ASSEMBLY BIOSCIENCES, INC. 8K

Assembly Biosciences announced year-end 2025 results, highlighted by licensing its genital herpes HPI program to Gilead, advancing its hepatitis pipeline, and significantly reducing its annual net loss while extending cash runway into 2028.

Assembly Biosciences, Inc. reported its financial results for the year ended December 31, 2025, highlighted by the successful licensing of its helicase-primase inhibitor program for recurrent genital herpes (including ABI-5366 and ABI-1179) to Gilead Sciences for a net $35 million option fee following positive Phase 1b data, completion of Phase 1a/b dosing and follow-up for those candidates, and advancement of its broader antiviral pipeline with a planned Phase 2 initiation for ABI-6250 in chronic hepatitis delta virus by the end of 2026 and a partnering process underway for HBV candidate ABI-4334 after Gilead declined its option. The company reported strong growth in collaboration revenue from Gilead, improved its cash, cash equivalents and marketable securities balance to $248.1 million with a runway into 2028, modestly higher R&D and G&A expenses, and a sharply reduced net loss of $6.1 million versus 2024, while outlining multiple upcoming clinical and scientific milestones and conference presentations.

Filing Facts

CIK

1426800

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-115980

Alert Tier

6